| Fenofibrate |
Capsule (Micronized) |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Fenofibrate (40 mg and 120 mg) |
Tablet |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Fenofibrate (48 mg and 145 mg) |
Tablet |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Fenofibrate (54 mg and 160 mg) |
Tablet |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Fenofibric Acid |
Tablet |
II (Paddle) |
75 |
Phosphate buffer, pH 6.8 |
900 |
5, 15, 30, 45 and 60 |
2010/08/05 |
| Fenoprofen Calcium |
Capsule |
|
|
Refer to USP |
|
|
2008/11/25 |
| Fentanyl |
Transdermal |
VII (Reciprocating holder)- cylinder. |
30 cycles per minute. amplitude of
about 2m. |
Equimolar mixture of 0.005 M phosphoric acid solution, and 0.005 M sodium phosphate, monobasic monohydrate (pH ~ 2.6). at 32° C. Change the test samples into fresh pre-equilibrated release medium at the time points indicated. Remove the protective liner and place the film onto a piece of nylon netting with
adhesive facing the net. Secure the netting and transdermal system using
nylon tie wraps at the top and bottom of the cylinder on the holder. The adhesive side faces towards the media. |
250 mL for the 75 and 100 mcg/hr, 200 mL for the 50 mcg/hr and 150 mL for the 25 and 12.5 mcg/hr dosage strength. |
0.5, 1, 2, 4 and 24 hours |
2011/06/09 |
| Fentanyl Citrate |
Tablet (Sublingual) |
II (Paddle) |
50 |
Phosphate Buffer, pH 6.8 |
500 |
1, 3, 5, 7, 10, 15 and 20 |
2013/08/15 |
| Fentanyl Citrate |
Lozenges |
II (Paddle) |
175 |
0.1 M Phosphate Buffer, pH 4.5 |
500 |
5, 10, 20, 30 and 40 |
2009/05/20 |
| Fentanyl Citrate (0.1 mg and 0.4 mg) |
Tablet (Buccal) |
II (Paddle) small volume dissolution apparatus |
100 |
Phosphate Buffered Saline solution, pH 7.0 |
100 |
3, 5, 7.5, 10, 15 and 20 |
2009/11/20 |
| Fentanyl Citrate (0.2 mg, 0.3 mg, 0.6 mg and
0.8 mg) |
Tablet (Buccal) |
II (Paddle) small volume dissolution apparatus |
100 |
Phosphate Buffered Saline solution, pH 7.0 |
200 |
3, 5, 7.5, 10, 15 and 20 |
2009/11/20 |
| Fentanyl Citrate (0.2 mg, 0.4 mg, 0.6 mg and
0.8 mg) |
Film (Buccal) |
I (Basket) 100 mL dissolution vessel |
100 |
25-mM Phosphate Buffer, pH 6.4 |
60 |
5, 10, 15, 20, 30 and 45 |
2009/12/15 |
| Fentanyl Citrate (1.2 mg) |
Film (Buccal) |
I (Basket) 100 mL dissolution vessel |
100 |
25-mM Phosphate Buffer, pH 6.4 |
100 |
5, 10, 15, 20, 30 and 45 |
2009/12/15 |
| Ferric Citrate |
Tablet |
II (Paddle) |
100 |
EDTA media ( 2.0 grams of EDTA Na2 2H2O to 1000 mL of purified water) |
900 |
10, 20, 30, 45 and 60 |
2015/08/27 |
| Ferric Maltol |
Capsule |
II (Paddle with sinker) |
75 |
Tier 1: KCl/HCl Buffer, pH 1.2; Tier 2: KCl/HCl Buffer pH 1.2, with pepsin |
1000 |
5, 10, 20, 30 and 45 |
2020/01/30 |
| Ferrous Fumarate |
Tablet |
|
|
Refer to USP |
|
|
2016/03/17 |
| Fesoterodine Fumarate |
Tablet (Extended Release) |
II (Paddle) with sinker |
75 |
Phosphate Buffer, pH 6.8 |
900 |
1, 2, 4, 6, 8, 10, 12, 16 and 20 hours |
2013/08/15 |
| Fexinidazole |
Tablet |
II (Paddle) |
75 |
0.1 N HCl with 3% w/v SLS |
2000 |
10, 20, 30, 40, 50 and 60 |
2023/05/18 |
| Fexofenadine HCl |
Tablet |
II (Paddle) |
50 |
0.001 N HCl |
900 |
5, 10, 20, 30 and 45 |
2004/02/19 |
| Fexofenadine HCl |
Capsule |
|
|
Develop a dissolution method |
|
|
2023/09/15 |